Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means that Cinderella stories like Wichita State have busted brackets of would-be basketball prognosticators.
Here at The Motley Fool, we decided to stick with what we know -- trading our basketball picks in for stock picks. We formed our own bracket filled with the top big pharma and big biotech stocks in a winner-take-all tournament determined by the collective intelligence of our CAPS community.
This Elite 8 matchup features a heavyweight bought between Celgene and Gilead. Watch and find out which stock gets eliminated and which will advance to the next round.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today simply click here now.
The article Health Care's Elite Eight Stocks: Celgene vs. Gilead originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.